Biotech News
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials Expands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially approved therapies Akron Bio is expected to generate approximately $28 million
